EPAS1 and neoplasm: The inhibition of EMMPRIN in melanoma can represent an alternative therapeutic strategy as it is expected to inhibit cell growth and invasion through the simultaneous inhibition of the VEGFR-2/VEGF system and the matrix degrading proteases and possibly other tumor promoting HIF-2α targets.